Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target

Gilead said it expects sales for its HIV portfolio to increase 6% in 2026 compared to 2025, spearheaded by growth in its recently launched pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir). Gilead’s HIV drugs generated $20.8bn in full-year 2025 sales, up 6% from 2024. This was mainly fuelled by the company’s well-established Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) market leadership. The once-daily HIV prevention pill’s sales increased 7% to$ 14.3bn. The drugmaker expects the HIV p ...